Cabenuva Demonstrates Superiority to Daily Oral Therapy in Adolescents Living With HIV, as ViiV Healthcare Highlights New Long-Acting Injectable Data at AIDS 2026
July 30, 2026
July 30, 2026
LONDON, England, July 30 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on July 29, 2026:
* * *
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
* Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva
. . .
* * *
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
* Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva
. . .